Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158651 · ClinicalTrials.gov registry record · Phase 2
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01158651 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants.
The verdict
NCT01158651, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied. The study drug, RAD001, is a drug that may act directly on tumor cells by preventing tumor cell growth and development. RAD001 has been studied in participants with various types of cancer as a single agent (a drug that is used alone to treat the cancer) or in combination with a number of well known anticancer therapies. Information from these research studies suggests that RAD001 may help to shrink or slow the growth of low-grade gliomas. In this research study, the investigators are looking to see the response of RAD001 in children with low-grade gliomas and NF1 that have either not responded to treatment or have come back after treatment. We are also looking for the highest dose of RAD001 that can be given safely in this patient population.
Interventions
- DRUG RAD001 (Everolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-07-10 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158651
The ClinicalTrials.gov registry entry for NCT01158651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 (Everolimus) is the first listed.
NCT01158651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158651 about?
NCT01158651 is a clinical study titled "Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas". The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied. The study drug, RAD001, is a drug that may act directly on tumor cells by p...
What is the current status of trial NCT01158651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-07-10. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT01158651?
The interventions under investigation include: RAD001 (Everolimus) (DRUG).
Who is sponsoring clinical trial NCT01158651?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.